Twan Sia, Leeon Bacchus, Aparna Kumar, Lina Fikri, Rachel Solecki, Ramin Herath, Yeelin Bacchus, Audrey Apollon, Margaret Werd, Aseelah Ashraf, Elaine Wu, Dan Bahar, John Leung
{"title":"Dupilumab for adult and adolescent patients with primary eosinophilic colitis.","authors":"Twan Sia, Leeon Bacchus, Aparna Kumar, Lina Fikri, Rachel Solecki, Ramin Herath, Yeelin Bacchus, Audrey Apollon, Margaret Werd, Aseelah Ashraf, Elaine Wu, Dan Bahar, John Leung","doi":"10.14309/ctg.0000000000000908","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Eosinophilic colitis (EoC) currently has limited options to induce histologic and clinical remission. Dupilumab is a human monoclonal antibody against the interleukin-4 receptor ɑ subunit effective in eosinophilic esophagitis (EoE) and other non-EoE eosinophilic gastrointestinal disorders (non-EoE EGIDs).</p><p><strong>Methods: </strong>We conducted a retrospective chart review to assess the histoclinical response of patients with EoC treated with dupilumab.</p><p><strong>Results: </strong>Of 4 included patients, all 4 improved histologically, with 3 patients attaining histologic remission. All patients' symptom scores significantly improved, and 1 patient was asymptomatic on dupilumab.</p><p><strong>Discussion: </strong>This retrospective case series provides preliminary evidence that dupilumab may be an effective treatment option for EoC.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14309/ctg.0000000000000908","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Eosinophilic colitis (EoC) currently has limited options to induce histologic and clinical remission. Dupilumab is a human monoclonal antibody against the interleukin-4 receptor ɑ subunit effective in eosinophilic esophagitis (EoE) and other non-EoE eosinophilic gastrointestinal disorders (non-EoE EGIDs).
Methods: We conducted a retrospective chart review to assess the histoclinical response of patients with EoC treated with dupilumab.
Results: Of 4 included patients, all 4 improved histologically, with 3 patients attaining histologic remission. All patients' symptom scores significantly improved, and 1 patient was asymptomatic on dupilumab.
Discussion: This retrospective case series provides preliminary evidence that dupilumab may be an effective treatment option for EoC.
期刊介绍：
Clinical and Translational Gastroenterology (CTG), published on behalf of the American College of Gastroenterology (ACG), is a peer-reviewed open access online journal dedicated to innovative clinical work in the field of gastroenterology and hepatology. CTG hopes to fulfill an unmet need for clinicians and scientists by welcoming novel cohort studies, early-phase clinical trials, qualitative and quantitative epidemiologic research, hypothesis-generating research, studies of novel mechanisms and methodologies including public health interventions, and integration of approaches across organs and disciplines. CTG also welcomes hypothesis-generating small studies, methods papers, and translational research with clear applications to human physiology or disease.
Colon and small bowel
Endoscopy and novel diagnostics
Esophagus
Functional GI disorders
Immunology of the GI tract
Microbiology of the GI tract
Inflammatory bowel disease
Pancreas and biliary tract
Liver
Pathology
Pediatrics
Preventative medicine
Nutrition/obesity
Stomach.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
